Compare Moderna, Inc. (MRNA) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Wipro Limited — how do they compare? Moderna, Inc. trades at $63.53 (market cap $24.18B), while Wipro Limited trades at $1.95 (market cap $19.07B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Wipro Limited pays a 4.4% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | WIT | |
|---|---|---|
Market Cap | $24.18B | $19.07B |
Sector | Health | Technology |
52-Week High | $81.80 | $3.06 |
52-Week Low | $22.36 | $1.78 |
Enterprise Value | $20.33B | $17.16B |
Dividend Yield | — | 4.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
WIT trades at $1.955, down 1.76% today, with a mixed technical picture showing a bullish overall signal but bearish moving averages. Fundamentally, the company reported strong 2025 results with $131.35B net income and a 14.74% margin, though recent quarters have seen earnings misses. Recent news highlights partnerships with Databricks and ServiceNow to advance AI capabilities.
The outlook is cautious; while valuation ratios appear reasonable and cash flow is positive, earnings misses and a mixed analyst consensus suggest near-term headwinds. Key risks include competitive pressures in IT services and macroeconomic uncertainty affecting client spending. The stock presents a value opportunity but requires monitoring of execution on AI initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
